Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

September 30, 2026

Conditions

Dyslipidemias

Interventions

DRUG

RBD5044

RBD5044, active drug.

DRUG

Placebo

Placebo that is identical in appearance and volume to the doses of active IMP.

Trial Locations (3)

RECRUITING

Lunds Universitetssjukhus, Lund

RECRUITING

Ribocure Clinic/Ribocure Pharmaceuticals AB, Mölndal

RECRUITING

Akademiska Sjukhuset Uppsala, Uppsala

All Listed Sponsors

lead

Ribocure Pharmaceuticals AB

INDUSTRY